---
title: "Varegacestat (AL102) in Desmoid tumors: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Co-prescribed/Concomitant therapies. Topics: Prohibited concomitant medications and excluded co-medications, Electrolyte supplementation and medical management of diarrhea, Prior and concurrent desmoid tumor therapies excluded from trial eligibility, and Analgesic use and anti-infective therapy in trial eligibility. 4 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Prohibited concomitant medications and excluded co-medications

> “The prohibited concomitant medications included herbal supplements”
> “conditions requiring chronic systemic glucocorticoid use, therapeutic anticoagulation, and concomitant second malignancies”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.12-2"></a>

### Electrolyte supplementation and medical management of diarrhea

> “excluding asymptomatic electrolyte abnormalities that were manageable with appropriate supplements, alopecia and fatigue lasting ≤5 days”
> “except hyperlipidemia in subjects not receiving maximum medical management or electrolyte abnormalities that may be managed with supplements”
> “Although Gr 3/4 diarrhoea related to the study treatment was observed in 2 of 7 patients (29%) treated at this dose level, these events resolved to Gr 1 within 24 h with appropriate medical management.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.12-3"></a>

### Prior and concurrent desmoid tumor therapies excluded from trial eligibility

> “Any treatments for desmoid tumors within 4 weeks prior to first dose of investigational therapy; subject must have recovered from therapy related toxicity to < CTCAE Grade 2 or clinical baseline. Therapy includes:”
> “Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery”
> “Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.12-4"></a>

### Analgesic use and anti-infective therapy in trial eligibility

> “Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication”
> “Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP such as known active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at Screening.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
